Advertisement

Radiopharmaceutical Therapy Targeting PSMA for Prostate Cancer

A panel of experts along with a patient and caregiver discuss the emergence of PSMA-targeting therapy for patients with metastatic castration resistant prostate cancer (mCRPC).

EP. 1: Overview of Metastatic Castration Resistant Prostate Cancer (mCRPC)

June 1st 2022

An overview of metastatic castration-resistant prostate cancer (mCRPC) and the role of PSMA in mCRPC.

EP. 2: Importance and the Process of PSMA PET Imaging in mCRPC

July 1st 2022

Jeremie Calais, MD, comments on how PSMA PET scans have changed the treatment landscape for patients with mCRPC and describes the process for obtaining a PSMA PET scan, including what patients should know before, during and after the scan.

EP. 3: mCRPC Diagnosis: The Patient and Caregiver Experience

July 1st 2022

Joseph Wood, a patient, and Deborah Wood, Joseph’s wife and caregiver, talk about Joseph’s prostate cancer diagnosis and Deborah explains her role as a caregiver.

EP. 4: Front-Line Treatment Options for Patients with mCRPC

July 13th 2022

Dr Matthew Rettig reviews the front-line treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) and what factors are considered when choosing appropriate treatment.

EP. 5: Emergence of PSMA Targeted Radioligand Therapy

July 13th 2022

Dr Jeremie Calais talks about the emergence and importance of PSMA-targeted radioligand therapy.

EP. 6: VISION Trial of Lutetium-177-PSMA-617 in mCRPC: Clinical Implications

July 26th 2022

Dr Jeremie Calais reviews the VISION trial and the implications of the data in the treatment paradigm for metastatic castration-resistant prostate cancer (mCRPC).

EP. 7: Treatment Journey Shared by a Patient with mCRPC and his Caregiver

July 26th 2022

Joseph Wood details his treatment journey with metastatic castration-resistant prostate cancer (mCRPC) and how the journey has impacted his wife and caregiver, Deborah Wood.

EP. 8: Clinical Considerations Related to Lutetium 177– PSMA-617 Treatment in mCRPC

August 2nd 2022

Dr Jeremie Calais shares some clinical pearls for lutetium-177 PSMA 617 and how this therapy has changed the treatment landscape for patients with metastatic castration resistant prostate cancer (mCRPC).

EP. 9: A Multi-Disciplinary Approach to Treatment for Patients with mCRPC

August 2nd 2022

Drs Matthew Rettig and Jeremie Calais explain what it means to be a part of a collaborative team and how communication plays a big role in patients receiving optimal treatment.

EP. 10: Follow-up and Side Effects in Patients Treated with Lutetium 177-PSMA 167

August 8th 2022

Joseph Wood and his wife and caregiver, Deborah, share their concerns and questions about radioligand therapy and how the COVID-19 pandemic has impacted their treatment experience.

EP. 11: Support and Advice for Patients with mCRPC and Their Caregivers

August 11th 2022

Joseph Wood and his caregiver, Deborah Wood, provide advice for patients and caregivers with prostate cancer who may be in similar situations, and comment on the support they have received from their family and community.

Advertisement
Advertisement